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Abstract
Background:  BMP-5 is expressed in the nervous system throughout development and into
adulthood. However its effects on neural tissues are not well defined. BMP-5 is a member of the
60A subgroup of BMPs, other members of which have been shown to stimulate dendritic growth
in central and peripheral neurons. We therefore examined the possibility that BMP-5 similarly
enhances dendritic growth in cultured sympathetic neurons.
Results:  Sympathetic neurons cultured in the absence of serum or glial cells do not form
dendrites; however, addition of BMP-5 causes these neurons to extend multiple dendritic
processes, which is preceded by an increase in phosphorylation of the Smad-1 transcription factor.
The dendrite-promoting activity of BMP-5 is significantly inhibited by the BMP antagonists noggin
and follistatin and by a BMPR-IA-Fc chimeric protein. RT-PCR and immunocytochemical analyses
indicate that BMP-5 mRNA and protein are expressed in the superior cervical ganglia (SCG) during
times of initial growth and rapid expansion of the dendritic arbor.
Conclusions:  These data suggest a role for BMP-5 in regulating dendritic growth in sympathetic
neurons. The signaling pathway that mediates the dendrite-promoting activity of BMP-5 may involve
binding to BMPR-IA and activation of Smad-1, and relative levels of BMP antagonists such as noggin
and follistatin may modulate BMP-5 signaling. Since BMP-5 is expressed at relatively high levels not
only in the developing but also the adult nervous system, these findings suggest the possibility that
BMP-5 regulates dendritic morphology not only in the developing, but also the adult nervous
system.
Background
Bone morphogenetic proteins (BMPs) are secreted sign-
aling molecules of the TGF-β  superfamily that have been
implicated in the control of a host of critical developmen-
tal phenomena in the central and peripheral nervous sys-
tems [1–3]. BMP-5, one of the more prominently
expressed BMPs in the nervous system, has been detect-
ed in multiple regions of the nervous system throughout
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development and into adulthood [3–6], yet its biological
activities in the nervous system are not well defined. A
role for BMP-5 in dorsal forebrain patterning has been
proposed based on its expression in the dorsal midline of
the developing forebrain and observations that ectopic
expression of BMP-5 in the developing neural tube of
chicks markedly downregulates ventral markers while
maintaining dorsal markers [5,7]. Further support for
BMP-5 regulation of early forebrain development has
been provided by studies of Bmp5/Bmp7 double mu-
tants [6]. However, reports that BMP-5 in the mouse
brain exhibits peak expression levels in the adult stria-
tum and brainstem and that maximal expression in the
hippocampus and cerebellum occurs at E18 through PN1
and again in the mature nervous system [3], suggest ad-
ditional roles for BMP-5 during later stages of neural de-
velopment and into adulthood.
BMPs have been divided into subgroups based on struc-
tural and evolutionary considerations [8]. Although
closely related BMPs have been shown to elicit distinct
cellular responses [5,9–13], members within a subgroup
often display conservation of not only structure, but also
function [4–6,14]. BMP-5 belongs to the 60A subgroup
of BMPs, which also includes BMP-6/Vgr-1, BMP-7/OP-
1, BMP-8a/OP-2, BMP-8b and Drosophila 60A [3,8].
Other members of the 60A subgroup have been shown to
modulate neuronal morphogenesis through selective ef-
fects on dendrites. Thus, BMPs 6, 7, and 60A stimulate
dendritic growth in cultured sympathetic neurons de-
rived from either perinatal or adult ganglia in the ab-
sence of effects on cell survival or axonal growth [15–17].
BMP-7 has also been shown to enhance dendritic growth
in hippocampal, cortical and spinal motor neurons [18–
20].
Whether BMP-5 similarly promotes dendritic growth
has not been previously addressed. Since dendrites are
the primary site of synapse formation, we felt it was im-
portant to examine this possibility. Moreover, since den-
dritic remodeling occurs throughout the life of the
animal, such studies could suggest a function for BMP-5
in the adult nervous system. In this report, we demon-
strate that like other members of the 60A subgroup,
BMP-5 triggers robust dendritic growth in sympathetic
neurons in vitro coincident with activation of Smad-1.
Noggin and follistatin, soluble proteins known to func-
tion as physiological antagonists for BMP-7 [21], also in-
hibit the dendrite-promoting activity of BMP-5.
Furthermore, BMP-5 mRNA and protein are detected in
intact sympathetic ganglia and neuron/glia cocultures,
respectively, consistent with a proposed role for BMP-5
in regulating dendritic growth in sympathetic neurons in
vivo.
Results
BMP-5 induces dendritic growth in cultured sympathetic 
neurons
As previously reported [16], sympathetic neurons grown
in the absence of serum and glial cells fail to form den-
drites (Figure 1A); however when grown in the presence
of BMP-7, these neurons extend multiple dendrites (Fig-
ure 1B). Similarly, addition of recombinant human BMP-
5 to the culture medium elicits dendritic growth in sym-
pathetic neurons as evidenced by the presence of tapered
processes that are immunoreactive for MAP2 (Figure
1C). Comparative analyses of concentration-effect rela-
tionships for BMP-7 and BMP-5 (Figure 2), indicate
EC50 values for BMP-5 approximately 10-fold higher
than those of BMP-7; however maximally effective con-
centrations of these two growth factors have comparable
effects on sympathetic neurons as assessed by the per-
centage of neurons with dendritic growth, the number of
dendrites per cell, and the total dendritic length per cell.
Time course studies of dendritic growth in neurons ex-
posed to maximally effective concentrations of BMP-5
and BMP-7 reveal comparable temporal responses as
well (Figure 3). Both BMP-5 and BMP-7 elicit dendrite
formation in 90–100% of the neuronal cell population
within 24 to 48 hr (Figure 3A). The gradual increase in
the number of dendrites per cell throughout a 17-day
treatment with BMP-5 parallels that observed in sister
cultures exposed to BMP-7 during the same period (Fig-
ure 3B). Experiments in which cultured sympathetic
neurons were treated simultaneously with maximally ef-
fective concentrations of BMP-5 and BMP-7 indicate that
the effects of BMP-5 and BMP-7 on dendritic growth are
not additive (data not shown).
Treatment of sympathetic neurons with BMP-5 induces 
phosphorylation of Smad1
In most cell systems that have been examined, the pri-
mary signal transduction pathway for BMPs involves
phosphorylation of Smad-1 [22], and recent evidence
suggests that this is also true for BMP-7 induced dendrit-
ic growth in sympathetic neurons [23]. To determine if
BMP-5 initiates similar signaling events in sympathetic
neurons, cultured sympathetic neurons grown in the ab-
sence of glial cells were treated with BMP-5 for 30 or 60
min then analyzed by Western blotting using Abs specific
for total Smad-1 or for phosphorylated Smad-1. Phos-
phorylation of Smad-1 is evident within 30 min after ex-
posure to BMP-5 (Figure 4A) with significantly increased
pSmad-1 levels apparent at 60 min. In contrast, treat-
ment with BMP-5 did not alter levels of total Smad-1
(Figure 4B).BMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
Figure 1
BMP-5 promotes dendritic growth in cultured sympathetic
neurons. Non-neuronal cells were eliminated from SCG cul-
tures by treatment with anti-mitotic agent during the 2nd and
3rd days in vitro. Beginning on day 5, sympathetic neurons
were treated with either control medium (A), medium sup-
plemented with 50 ng/ml BMP-7 (B), or medium containing
300 ng/ml BMP-5 (C). Six days later, cultures were immunos-
tained with mAb against MAP2, a protein found primarily in
dendrites and neuronal somata. Neurons grown under con-
trol conditions lack dendrites (A). In contrast, neurons
exposed to BMP-7 (B) or BMP-5 (C) typically have several
tapered dendrites. Bar, 50 µm.
Figure 2
BMP-5 is less potent than BMP-7 but equally efficacious in
promoting dendritic growth in cultured sympathetic neurons.
Beginning on the fifth day in vitro after elimination of glial
cells, SCG neurons were exposed to varying concentrations
of BMP-5 or BMP-7. After 6 days of exposure to BMPs, cul-
tures were immunostained with a mAb to the dendritic
marker MAP2. Dendritic growth was quantified with respect
to the percent of cells with dendrites (A), number of den-
drites per neuron (B) and total dendritic length (C). Data in
panels B and C are presented as the mean ± S.E.M. (n = 60
per experimental condition). * p < 0.05.BMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
Figure 3
The time course of dendritic growth is comparable between
maximally effective concentrations of BMP-5 and BMP-7.
Beginning on the fifth day in vitro, SCG neurons grown in the
absence of glial cells were treated with control medium or
medium supplemented with maximally effective concentra-
tions of BMP-5 (300 ng/ml) or BMP-7 (50 ng/ml). After vary-
ing exposure times, cultures were fixed and immunostained
with mAb to the dendritic marker MAP2. Dendritic growth
was quantified with respect to the percent of cells with den-
drites (A) and the number of dendrites per neuron (B). Data
in panel B are expressed as the mean ± S.E.M. (n = 60 per
experimental condition). There were no significant differ-
ences between BMP-7 and BMP-5 at any time point at p <
0.05.
Figure 4
BMP-5 induces phosphorylation of Smad-1 in cultured sym-
pathetic neurons. (A) Blots of cell lysates from SCG cultures
consisting solely of neuronal cells were probed using Ab that
specifically recognizes the phosphorylated form of Smad-1.
Under control conditions (time = 0 min), phosphorylated
Smad-1 is not detected. Treatment with BMP-5 (100 ng/ml)
causes a time-dependent increase in the band density of
phosphorylated Smad-1. (B) Densitometric analyses of West-
ern blots of cell lysates from purified neuronal cell cultures at
varying times after exposure to BMP-5. Equal amounts of
protein were loaded into all wells and each blot was probed
initially for p-Smad, then stripped and successively probed for
total Smad and tubulin. Data are presented as the mean ±
S.E.M. (n = 2 per experimental condition).BMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
Antagonists of BMP- function inhibit BMP-5-induced den-
dritic growth
Recent data suggest that in the developing nervous sys-
tem, signaling by at least BMPs 2, 4 and 7 is determined
by the spatiotemporal expression patterns of BMPs and
their receptors, and by relative levels of the soluble BMP
antagonists such as follistatin and noggin that directly
bind BMPs in the extracellular compartment and pre-
vent functional receptor/ligand interaction [1,24–28].
The extent to which these factors may regulate BMP-5
signaling is difficult to determine because of the paucity
of data regarding either antagonism of BMP-5 signaling
by follistatin and noggin or the interaction between
known BMP receptors and BMP-5. To address the
former question, we tested the ability of follistatin and
noggin to block the dendrite-promoting activity of BMP-
5. The latter was evaluated indirectly using a recom-
binant chimeric protein containing the extracellular do-
main of the BMP receptor type IA fused to the
immunoglobulin Fc domain (BMPR-IA-Fc). The chimer-
ic protein containing BMPR-IA was chosen because it
has been previously reported that this is the predomi-
nant BMP receptor type expressed in embryonic and
postnatal superior cervical ganglia (SCG) [29]. As indi-
cated in Figure 5, follistatin and noggin significantly in-
hibit the dendrite promoting activity of BMP-5 in a
concentration-dependent manner. Maximally effective
concentrations of noggin (1000 ng/ml) and follistatin
(1000 ng/ml) reduce BMP-5-induced dendritic growth
by 77% and 72% respectively. The BMPR-IA-Fc chimera
also significantly inhibited BMP-5-induced dendritic
growth. Increasing the concentration of any of these an-
tagonists to levels greater than those expressed in Figure
5 did not cause greater inhibition of BMP-5-induced
dendritic growth (data not shown).
Expression of BMP-5 mRNA and protein in SCG cells
If BMP-5 is a physiological regulator of dendritic mor-
phogenesis in sympathetic neurons, then its spatiotem-
poral patterns of expression should be coincident with
dendritic growth in this neuronal cell type. Potential
sources of BMP-5 include neuronal and glial cells within
the ganglia. To examine this possibility, antibody (Ab)
specific for BMP-5 was used to immunostain cocultures
of SCG neurons and glial cell that had been cultured for
2 weeks to allow for significant expansion of the glial cell
population. The specificity of the BMP-5 Ab used in these
experiments is indicated by demonstrations that it rec-
ognizes purified recombinant BMP-5, but not purified
recombinant BMP-6 or BMP-7 in Western blots (Figure
6). Moreover, the reaction with BMP-5 protein is signifi-
cantly blocked by preincubation of the BMP-5 Ab with
blocking peptide (Figure 6). In SCG cultures immunos-
tained with this BMP-5 Ab, immunoreactivity is present
in most if not all ganglionic glial and neuronal cells (Fig-
Figure 5
Soluble BMP antagonists inhibit BMP-5-induced dendritic
growth. Beginning on the fifth day in vitro, SCG neurons
were exposed to BMP-5 (100 ng/ml) in the absence or pres-
ence of varying concentrations of follistatin (A), noggin (B) or
the BMP-RIA-Fc chimera (C). On the tenth day in vitro, cul-
tures were immunostained with mAb to nonphosphorylated
forms of the M and H neurofilaments to visualize dendrites.
Dendritic growth was quantified with respect to the number
of dendrites per neuron expressed as the mean ± S.E.M. (n =
50 per experimental condition). * Indicates a significant differ-
ence from negative control values (- BMP-5/- antagonist) indi-
cated by the dashed line in each bar graph at p < 0.01 and **
from positive control values (+ BMP-5/- antagonist) at p <
0.01.BMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
ure 7A and 7B). In glial cells, fluorescence is present
throughout the cell but excluded from the nucleus; in
neurons, immunoreactivity is evident in both the soma
and processes. Preincubation of the BMP-5 Ab with spe-
cific blocking peptide (Figure 7C and 7D) reduced BMP-
5 immunoreactivity to levels comparable to those ob-
served in control cultures reacted with the secondary Ab
only (Figure 7E and 7F).
BMP-5 expression in vivo was assessed by RT-PCR anal-
yses of SCG harvested from rats of different ages corre-
sponding to various stages of dendritic growth in
sympathetic neurons. As indicated in Figure 8, BMP-5
mRNA is present in SCG at embryonic day 20 (E20),
which corresponds to the period of initial extension of
primary dendrites, and at postnatal days 3 and 7 (PN3
and PN7), which corresponds to the period of maximal
dendritic growth. In contrast, BMP-5 mRNA was not de-
tected in adult SCG.
Discussion
BMP-5 is widely expressed in the nervous system
throughout development and into adulthood [3–6], yet
the only function described for this growth factor thus far
is dorsal patterning of the developing forebrain [5–7].
Our data suggest that BMP-5 may also regulate later
stages of neural development, specifically dendritic mor-
phogenesis. The most direct support for this hypothesis
is the finding that addition of BMP-5 to sympathetic neu-
rons in culture causes these cells to extend multiple den-
dritic processes. These data are consistent with
conclusions from previous studies indicating that den-
drite-promoting activity is restricted to BMPs from the
60A or dpp (BMPs 2 and 4) subgroups and is not ob-
served with BMPs from other subgroups such as BMP-3,
BMP-13 or dorsalin, or with other members of the TGF-
β  superfamily such as activin, TGF-β 1, -β 2 or -β 3 [16,17].
Functional redundancy between BMPs of the 60A sub-
group has been previously reported with respect to other
developmental endpoints [6], of which some, such as up-
regulation of cell adhesion molecules [30], may be di-
rectly relevant to effects on dendritic growth. BMP-6 and
BMP-7 as well as dpp subgroup members, BMP-2 and
BMP-4, have been shown to influence other aspects of
sympathetic neuron development, such as differentia-
tion of adrenergic sympathetic neurons from neural crest
[13,31–38] and neuropeptide phenotype [39]. It will be
of interest to determine if BMP-5 also exhibits functional
redundancy with respect to these effects.
Pharmacological studies of BMP-5 indicate that relative
to BMP-7, BMP-5 is less potent but equally efficacious in
promoting dendritic growth in cultured sympathetic
neurons. These data, together with observations that
maximally effective concentrations of BMP-5 and BMP-
7 are not additive, suggest that the two ligands share as-
pects of a common signaling pathway. It has been shown
that phosphorylation of Smad-1 precedes dendritic ex-
tension in cultured sympathetic neurons exposed to
BMP-7; moreover, expression of a dominant negative
construct of Smad-1 in cultured sympathetic neurons
significantly inhibits BMP-7-induced dendritic growth in
these neurons [23]. These data suggest that activation of
Smad-1 is a necessary component of the signal transduc-
tion pathway by which BMP-7 induces dendritic growth.
In this report we demonstrate that BMP-5 similarly in-
duces Smad-1 phosphorylation in sympathetic neurons
as detected by Western blot analyses using antibodies
specific for the phosphorylated form of Smad-1. These
data suggest conserved mechanisms of signaling within
the 60A subgroup. The molecular mechanism(s) of
BMP-induced dendritic growth downstream of Smad-1
activation are not well characterized. Previous studies
have demonstrated that transcriptional and translation-
al events are required for dendritic growth in response to
BMPs [15], but the gene expression profile responsible
for BMP-induced dendritic growth has yet to be deter-
mined. Thus, it is not clear if BMP-5 or -7 induces den-
dritic growth directly, or if some other factor made by the
cells in response to BMPs is responsible for initiating
dendritic growth.
BMPs activate Smad-1 by binding to type I and type II
serine-threonine kinase receptors [40,41]. Specific re-
Figure 6
The specificity of the BMP-5 Ab used in these studies as
assessed by Western blot analysis. BMP-5 Ab (0.5 µg/ml)
reacts with purified recombinant BMP-5 (50 ng), but not with
equal amounts of purified recombinant BMP-6 or -7. Preincu-
bation of BMP-5 Ab with specific blocking peptide (2.5 µg/ml)
significantly reduces binding to BMP-5 protein. Data repre-
sented in this figure were obtained from the same immunob-
lot.BMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
Figure 7
BMP-5 immunoreactivity is detected in co-cultures of SCG neurons and glia. Phase contrast (A,C,E) and fluorescence (B,D,F)
micrographs of SCG cultures immunostained for BMP-5 after 10 days in vitro. Both glial cells and neurons express significant
BMP-5 immuno-reactivity, and in neurons, the processes as well as the soma are brightly stained (A,B). Preincubation of BMP-
5 Ab with blocking peptide prior to reaction with SCG cultures (C,D) reduces the intensity of immunostaining to levels com-
parable to the background fluorescence observed in SCG cultures reacted only with secondary Ab (E,F).BMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
ceptor subunits shown to bind BMPs include BMP recep-
tor type IA (BMPR-IA), BMPR-IB, BMR-II, activin
receptor type I (ActR-I), and ActR-II [42–44]. BMP lig-
ands can bind to either type I or type II receptor subunits
independently, but both receptor types are required for
high-affinity binding and signaling [40]. The finding that
the soluble BMPR-IA-Fc chimera significantly inhibits
BMP-5 induced dendritic growth suggests that BMP-5
may be activating the Smad-1 signaling pathway via in-
teractions with BMPR-IA. Although the physiological
relevance of this finding has yet to be confirmed by lig-
and binding studies using endogenous neuronal BMPR-
IA, these data are consistent with reports that BMPR-IA
is the predominant BMP receptor type expressed in em-
bryonic and postnatal superior cervical ganglia (SCG)
[29].
It is becoming increasingly evident that BMP signaling is
regulated not only by the spatiotemporal expression of
BMP ligands and receptors, but also by relative levels of
soluble BMP antagonists, which directly bind BMPs and
prevent functional receptor/ligand interaction [1,24–
28]. The different BMP antagonists bind to BMPs and
other TGF-β  family members with varying degrees of
specificity. For example, follistatin binds both activin
and BMP-7 avidly but competes weakly or not at all with
the type I receptor for BMP-4 binding [25,45], whereas
noggin binds to BMPs -2 and -4 with greater affinity than
BMP-7 [46]. Whether BMP-5 function can be antago-
nized by noggin or follistatin has not been previously re-
ported, but our results suggest that simultaneous
addition of either antagonist with BMP-5 significantly
inhibits the dendrite-promoting activity of BMP-5 in a
concentration-dependent manner. Thus, profiling the
BMP binding affinities as well as the expression patterns
of these BMP antagonists will be critical to understand-
ing the regulation of BMP-5 signaling in the nervous sys-
tem.
If BMP-5 is important in regulating dendritic growth in
intact ganglia, its expression should correlate with peri-
ods of dendritic growth in vivo. In sympathetic ganglia,
dendritic growth begins prenatally and maximal expan-
sion of the dendritic arbor occurs during postnatal weeks
1 and 2 [47,48]. RT-PCR analyses of intact SCG indicate
that cells of the SCG express BMP-5 transcripts from E20
through P7. Preliminary observations indicate that these
BMP-5 transcripts are translated into protein in SCG in
vivo as assessed by Western blot analyses using BMP-5
Ab (P. Lein, unpublished observations). Earlier studies
have demonstrated the expression of BMP-4 transcripts
in developing avian sympathetic ganglia [49], suggesting
the presence of multiple BMPs in sympathetic ganglia
throughout development. These data, in conjunction
with observations that mRNA for BMP type IA and type
II receptors are expressed in the developing sympathetic
ganglia [29], are consistent with a potential role for
BMP-5 in regulating the initiation and rapid expansion
of the dendritic arbor in sympathetic ganglia of perinatal
animals.
The cellular distribution of BMP-5 was determined by
immunocytochemistry in sympathetic neurons cocul-
tured with ganglionic glial cells. Both neurons and glial
cells express BMP-5 protein. In situ hybridization analy-
ses of BMP-6 and BMP-7 indicate that both cell types
also express BMP transcripts (P. Lein, unpublished ob-
servations). These findings are consistent with previous
reports that dendritic growth can be induced in sympa-
thetic neurons in vitro when cultured at high neuronal
cell density [50] or in the presence of ganglionic glial
cells [51].
Dendritic growth continues, albeit to a lesser extent, into
adulthood, and dendritic remodeling occurs throughout
the animal's life. Mature sympathetic neurons cultured
from adult animals respond to BMP-7 with enhanced
dendritic growth [15], and treatment with BMP-7 en-
hances recovery in animal models of stroke [52–56]. Al-
though BMP-5 mRNA was not detected in adult SCG,
Western blot analyses indicate that BMP-5 protein is
present in adult SCG (P. Lein, unpublished observa-
tions), presumably derived from nonganglionic sources
Figure 8
BMP-5 mRNA is expressed in SCG at times corresponding
to maximal dendritic growth in SCG neurons. BMP-5 mRNA
was detected by RT-PCR in total RNA extracted from rats
SCG at E20, PN3 and PN7, which correspond to times of ini-
tial dendrite extension (E20) and maximal expansion of the
dendritic arbor (PN3 and PN7). In contrast, PCR product
was not detected in equal amounts of total RNA isolated
from adult SCG.BMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
such as serum or target tissues. These observations to-
gether with reports that BMP-5 is expressed at signifi-
cant levels in the adult nervous system [3] suggest a
potential role for BMP-5 in modulating dendritic mor-
phology not only during development, but also in adult
nervous systems.
Conclusions
These data suggest that BMP-5 regulates dendritic
growth. Addition of BMP-5 to sympathetic neurons in
culture triggers significant dendritic growth that is con-
centration-dependent. Data from western blot analyses
using Ab specific for phosphorylated epitopes of Smad-1
as well as analyses of dendritic growth in cultures ex-
posed to BMP-5 in the presence of a soluble BMPR-IA-Fc
chimeric protein are consistent with a signaling pathway
that involves binding to the BMPR-IA and activation of
Smad-1. BMP-5 signaling may be modulated by noggin
and follistatin since these BMP antagonists were ob-
served to inhibit the dendrite-promoting activity of
BMP-5. Spatiotemporal patterns of BMP-5 expression at
the mRNA level, as assessed by RT-PCR, and the protein
level, as determined by immunocytochemistry corre-
spond to periods of initial dendritic growth and rapid ex-
pansion of the dendritic arbor. These observations,
together with previously published reports from other
laboratories indicating significant levels of BMP-5 ex-
pression in the developing and adult nervous system [3]
suggest a potential role for BMP-5 in modulating den-
dritic morphology not only during development, but also
in adult nervous systems.
Materials and Methods
Materials
Purified human recombinant BMPs (5, 6 and 7) were
prepared using previously published methods [57] and
provided by Creative Biomolecules (Hopkinton, MA). Af-
finity-purified polyclonal antibody (Ab) specific for
BMP-5, the blocking peptide for the BMP-5 Ab, and the
recombinant human BMP-RIA-Fc chimera were pur-
chased from Research Diagnostics (Flanders, NJ). Ab
specific for the phosphorylated form of Smad-1 (Ser 463/
465) as well as Ab that recognizes both phosphorylated
and nonphosphorylated Smad-1 (e.g., total Smad-1) was
purchased from Upstate Biological (Lake Placid, NY).
Xenopus noggin protein [58] was the generous gift of
Drs. Josè de Jesús and Richard Harland (UC at Berke-
ley). Recombinant human follistatin (B4384) was ob-
tained through Dr. A.F. Parlow at the NHPP, NIDDK
(Torrance, CA).
Tissue culture
Sympathetic neurons were dissociated from the SCG of
perinatal (E21 to PN1) Holtzmann rats (Harlan Sprague-
Dawley, Rockford, IL) according to previously described
methods [59]. Cells were plated onto glass coverslips (for
immunocytochemical and morphological studies) or 35
mm plastic culture dishes (for Western blot analyses)
precoated with 100 µg/ml poly-D-lysine (Sigma, St. Lou-
is, MO). Cultures were maintained in serum-free medi-
um supplemented with β -NGF (100 ng/ml), bovine
serum albumin (500 µg/ml), insulin (10 µg/ml), and
transferrin (20 µg/ml). In most experiments, endog-
enous non-neuronal cells were eliminated from cultures
by adding cytosine-β -D-arabinofuranoside (Sigma, St.
Louis, MO) to the culture medium at 1 µM for 48 hr be-
ginning on day 2. In some experiments this antimitotic
was not added to cultures but rather endogenous non-
neuronal cells were allowed to proliferate. Previous stud-
ies have demonstrated that under these culture condi-
tions, the non-neuronal cells are primarily ganglionic
glia [51].
Morphological analyses
Dendritic growth was assessed in cultures immunos-
tained with monoclonal antibodies (mAb) previously
shown to react selectively with the somatodendritic com-
partment of cultured sympathetic neurons [16]. These
mAb's include SMI-52, which is specific for the cytoskel-
etal protein MAP2, and SMI-32, which reacts with the
non-phosphorylated forms of the M and H neurofila-
ment subunits (Sternberger Immunocytochemicals, Bal-
timore, MD). Antigens were localized by indirect
immunofluorescence as previously described [16]. Den-
dritic growth was quantified using SPOT image analysis
system. Data in the text are presented as the mean ±
S.E.M. and statistical significance was determined using
ANOVA followed by Tukey's test.
Western blot analyses
Western blot analyses were performed on purified re-
combinant BMPs to assess the specificity of the BMP-5
Ab, and on cell lysates of cultured sympathetic neurons
to assess the effects of BMP-5 on phosphorylation of
Smad1 as well as levels of total Smad (nonphosphorylat-
ed and phosphorylated). Cell lysates were obtained by
rinsing 12-day old neuronal cell cultures with ice-cold
phosphate-buffered saline prior to trituration in ice-cold
lysis buffer (PBS supplemented with 1% Igepal, 0.5% so-
dium deoxycholate, 0.1% SDS, 100 µg/ml PMSF and 300
µg/ml aprotinin). Cell lysates were microfuged at maxi-
mum speed for 5 min and the resultant supernatant col-
lected. Protein concentration was determined using the
Bradford assay (BioRad, Hercules, CA). Samples con-
taining equivalent amounts of protein were resolved by
12% polyacrylamide SDS PAGE under reducing condi-
tions and then electroblotted onto PVDF membranes.
Blots were blocked at room temperature for 1 hour in
TBS-T (10 mM Tris, pH 8.0, 150 mM NaCl, 0.1% Tween-
20) containing 5% dried fat-free milk, then incubatedBMC Neuroscience 2001, 2:12 http://www.biomedcentral.com/1471-2202/2/12
overnight at 4°C in TBS-T containing 0.5% milk and pri-
mary Ab (0.5 µg/ml for BMP-5 Ab; 10 µg/ml for Smad-1
Ab). Blots were washed twice with TBS-T containing
0.5% milk, then incubated at room temperature for 2
hours in TBS-T containing 0.5% milk and 1:5000 dilu-
tions of secondary Ab conjugated to peroxidase (for
BMP-5, anti-goat IgG-peroxidase from Chemicon, Te-
mecula CA; for Smad1, anti-rabbit Ig-peroxidase from
Amersham, Piscataway, NJ). Subsequently, blots were
washed three times as described above, and visualized
using an enhanced chemiluminescence detection meth-
od (ECL, Amersham). Blots of cell lysates were stripped
and reprobed using antibodies specific for α -tubulin
(1:10,000, Sigma). To quantify data, films were scanned
using an HP ScanJet ADF scanner and HP Precision
ScanPro software, and band density determined as arbi-
trary absorption units using the MacBas software pro-
gram (version 2.31, Fuji Film).
Immunocytochemistry
BMP-5 Ab was used to localize BMP-5 protein in SCG
cultures containing sympathetic neurons and ganglionic
glial cells. After 2 weeks in culture, cells were fixed in 4%
paraformaldehyde, permeabilized with methanol at -
20°C (Sigma, St. Louis, MO), and then reacted with anti-
BMP-5 Ab (10 µg/ml). Immunoreactivity was visualized
by indirect immunofluorescence as previously described
[16]. The specificity of the immunoreaction was deter-
mined by preincubating the BMP-5 Ab with its specific
blocking peptide (100 µg/ml) prior to reaction with the
cultures.
RNA Isolation and Analyses
Total RNA was extracted from freshly harvested superior
cervical ganglia (SCG) using Trizol (Life Technology,
Carlsbad, CA). RNA samples (5 µg) were reverse tran-
scribed using random primers at annealing tempera-
tures of 65°C (You-Prime-the-First-Strand kit,
Amersham, Piscataway, NJ). Resultant cDNA was am-
plified by PCR for 35 cycles using an annealing tempera-
ture of 55°C for 30 sec and denaturing temperature of
95°C for 30 sec; the Mg++ concentration in these reac-
tions was 1.5 mM. As a negative control, each sample was
run through PCR without prior reverse-transcription.
Primers used for amplification of BMP-5 cDNA were de-
signed to unique sequences of rat BMP-5 using the
Primer3 program  [http://www-genome.wi.mit.edu/cgi-
bin/primer/primer3_www.cgi] . The specific primer se-
quences were BMP-5 sense, 5'-TTATGCAAAAGGAG-
GCTTGG-3' and BMP-5 antisense, 5'-
TCATGACCATGTCAGCATCA-3'. After synthesis, PCR
products were subjected to 1% agarose gel electrophore-
sis and found to have the expected size of 420 base pairs.
List of abbreviations
Ab, polyclonal antibody
BMP, bone morphogenetic protein
BMPR-IA, BMP receptor type IA
E20 or E21, embryonic day 20 or 21
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PN1, PN3 or PN7, postnatal day 1, 3 or 7
SCG, superior cervical ganglia
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